The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH
Top Cited Papers
Open Access
- 16 September 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 134 (18), 1528-1532
- https://doi.org/10.1182/blood.2019002600
Abstract
High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior outcomes after standard chemoimmunotherapy. We recently described a gene expression signature that identifies 27% of germinal center B-cell DLBCLs (GCB-DLBCLs) as having a double-hit–like expression pattern (DHITsig) and inferior outcomes; however, only half of these cases have both MYC and BCL2 translocations identifiable using standard breakapart fluorescence in situ hybridization (FISH). Here, 20 DHITsig+ GCB-DLBCLs apparently lacking MYC and/or BCL2 rearrangements underwent whole-genome sequencing. This revealed 6 tumors with MYC or BCL2 rearrangements that were cryptic to breakapart FISH. Copy-number analysis identified 3 tumors with MYC and 6 tumors with MIR17HG gains or amplifications, both of which may contribute to dysregulation of MYC and its downstream pathways. Focal deletions of the PVT1 promoter were observed exclusively among DHITsig+ tumors lacking MYC translocations; this may also contribute to MYC overexpression. These results highlight that FISH fails to identify all HGBL-DH/THs, while revealing a range of other genetic mechanisms potentially underlying MYC dysregulation in DHITsig+ DLBCL, suggesting that gene expression profiling is more sensitive for identifying the biology underlying poor outcomes in GCB-DLBCL.Keywords
This publication has 20 references indexed in Scilit:
- Identification of “Double Hit” Lymphomas Using Updated WHO Criteria: Insights From Routine MYC Immunohistochemistry in 272 Consecutive Cases of Aggressive B-Cell LymphomasApplied Immunohistochemistry & Molecular Morphology, 2019
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphologyBlood, 2018
- Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impactPublished by American Society of Hematology ,2017
- Manta: rapid detection of structural variants and indels for germline and cancer sequencing applicationsBioinformatics, 2015
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA studyBlood, 2015
- miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growthNature Communications, 2015
- Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)British Journal of Haematology, 2014
- A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphomaBlood, 2014
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell LymphomaCancer Cell, 2012
- Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing dataBioinformatics, 2011